Tumor-Derived FGF19

Launched by UNIVERSITY OF CENTRAL FLORIDA · Sep 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a protein called FGF19, which may help detect certain types of cancer, specifically breast and colorectal cancer. Researchers want to find out how well this protein can be identified in the blood of patients with these cancers compared to healthy individuals. The goal is to understand if FGF19 levels are higher in cancer patients, which could help in developing better tests for early cancer detection.

To participate in this study, you need to be an adult aged 18 or older, either with a diagnosis of breast or colorectal cancer or a healthy individual without cancer. Participants will be asked to provide a blood sample after fasting. It’s important to note that pregnant women can join the study, as it is designed to be safe for them and their babies. However, people who cannot give informed consent, minors, or prisoners will not be eligible to participate. If you join the study, you can expect a supportive environment where your contributions may help advance cancer research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The study will enroll adult persons with breast cancer or colorectal cancer or no cancer (healthy controls) who are able to do a fasting blood draw.
• • (Pregnant women may choose to be in the study. The study procedures do not pose a risk to the safety of the unborn child or the woman.)
• Exclusion Criteria:
• • The study will not enroll persons who are unable or unwilling to provide informed consent.
• • Adults unable to consent, individuals who are not yet adults, and prisoners will be excluded from this study.